Engineered Polypeptides for High-Capacity Immunoglobulin Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monoclonal antibody purification, particularly using Protein A affinity chromatography, are costly and face challenges with capacity limitations, stability issues, and high production costs, which hinder the affordability of therapeutic antibodies.
Innovation Solution
Engineered polypeptides that combine functional moieties of immunoglobulin-binding proteins like Protein A with synthetic oligopeptides, chemically conjugated or genetically fused, are used to create high-capacity separation matrices with improved binding capabilities and stability, allowing for efficient purification of immunoglobulins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If Protein A affinity chromatography is used for monoclonal antibody purification, then purification effectiveness is improved, but production cost increases significantly
Solution Approach 1:
The patent creates simplified copies of Protein A's immunoglobulin-binding function using small synthetic peptides (e.g., 4-10 amino acids) that replicate the essential binding capability. These peptide copies are chemically synthesized and conjugated to solid supports, providing a low-cost alternative to expensive native Protein A while maintaining purification effectiveness.
Solution Approach 2:
The invention employs inexpensive synthetic peptides that can be readily produced and replaced. These short-lived peptide ligands are conjugated to disposable solid support cartridges, eliminating the need for expensive, reusable Protein A columns and enabling cost-effective single-use purification systems.
2Reliability
If Protein A is used for antibody purification, then binding capability is improved, but stability under column washing and elution conditions deteriorates
Solution Approach 1:
The patent extracts only the essential immunoglobulin-binding functional domains from the full Protein A structure, isolating the specific amino acid sequences responsible for antibody binding. These extracted peptide motifs are then synthesized independently and conjugated to stable solid supports, separating the binding function from the unstable protein structure.
Solution Approach 2:
The invention replaces the protein-based Protein A system with a synthetic peptide-based system. This substitution uses chemically synthesized peptides with defined sequences conjugated to stable solid supports, replacing the biological protein system that is susceptible to degradation with a more stable synthetic alternative.
3Manufacturing precision
If Protein A affinity chromatography is used, then purification capacity is improved, but susceptibility to protease degradation increases
Solution Approach 1:
The patent creates protease-resistant copies of the Protein A binding function using synthetic peptides. These peptide copies lack the complex protein structure that proteases target, providing a degradation-resistant alternative that maintains purification capacity.
Solution Approach 2:
The invention substitutes the protein-based Protein A system with a synthetic peptide system that is inherently resistant to proteolytic degradation. The chemically synthesized peptides with defined sequences and stable conjugation to solid supports eliminate the susceptibility to protease attack that plagues native Protein A.
4Reliability
If Protein A is used for immunoglobulin purification, then binding effectiveness is improved, but the cost of therapeutic antibodies increases
Solution Approach 1:
The patent creates low-cost synthetic peptide copies that replicate Protein A's binding effectiveness. These peptides are chemically synthesized using standard peptide synthesis methods, which are far less expensive than producing and purifying native Protein A, thereby reducing the cost of therapeutic antibody production while maintaining binding effectiveness.
Solution Approach 2:
The invention employs inexpensive synthetic peptides that can be readily produced and used in disposable solid support cartridges. This approach eliminates the need for expensive, reusable Protein A columns and enables cost-effective purification that reduces the overall cost of therapeutic antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered polypeptides significantly increase the binding capacity and stability of immunoglobulin purification, reducing costs and enabling scalable, efficient production of therapeutic antibodies.
Implementation Method 1
an engineered polypeptide that binds immunoglobulins or immunoglobulin-containing compounds, the polypeptide comprising at least one functional moiety of at least one naturally occurring or recombinant immunoglobulin binding protein
Data Source
AI summary
Compositions and methods are provided for producing materials having increased immunoglobulin binding capacities, the materials including full-length or truncated forms of protein A, protein G, protein A/G, protein L and other immunoglobulin-binding proteins or peptides, which moieties contain polypeptide domains, or polypeptide-oligopeptide combinations. Also provided are separation matrices containing the moieties and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin containing proteins.